Summary

Molecular Diagnostics Market Analysis

The molecular diagnostics market size is expected to reach USD 20.41 billion in 2026 and is projected to grow to USD 33.51 billion by 2031, reflecting a 10.43% CAGR. Broadening reimbursement for genomic profiling and establishing clearer regulatory pathways for laboratory-developed tests are facilitating the transition of precision medicine from research to routine care. Sequencing costs below USD 200 per genome, FDA breakthrough device designations for rapid whole-genome platforms, and retail-clinic rollouts of CLIA-waived assays are expanding clinical access. Meanwhile, the European Union’s In Vitro Diagnostic Regulation (IVDR) heightens post-market surveillance and compresses margins for smaller manufacturers, consolidating demand around integrated platforms. Falling per-test prices, multiplex syndromic panel uptake in hospitals, and pharmaceutical vertical integration into in-house genomic services together accelerate adoption across oncology, infectious disease, and population health programs.

Global Molecular Diagnostics Market Trends and Insights



Growing Demand for Rapid Point-of-Care Molecular Diagnostics

Point-of-care platforms shorten diagnostic cycles from days to minutes, enabling immediate prescribing decisions and cutting inappropriate antibiotic use by 31% in urgent-care clinics. Handheld systems deliver results in under 15 minutes and integrate with electronic health records, matching the workflow of retail clinics where throughput drives profitability. Payers recognize downstream savings from reduced hospital readmissions, and parity reimbursement removes the historic cost advantage of centralized labs. Retail pharmacy chains announced nationwide deployments for respiratory panels in 2025, shifting high-volume testing away from emergency departments. As CLIA-waived clearances expand to chronic disease assays, consumer-initiated testing is set to become a routine component of primary care visits.

Integration of Companion Diagnostics with Targeted Therapies

Regulators now view companion diagnostics as prerequisites for most targeted therapies. The FDA cleared additional KRAS, NTRK, and HER2 biomarker-drug pairs in 2024, broadening single-run genomic profiling utility. EMA guidance mandates validation data at first drug filing, compressing the diagnostic-therapeutic development cycle but raising investment thresholds. Japan’s fast-track review shortens orphan-drug companion diagnostic approvals to 10 months, incentivizing the development of assays for rare mutations. Tumor mutational burden and microsatellite instability scores bundled into single workflows conserve tissue and accelerate reporting, making multi-biomarker panels the standard of care. Pharmaceutical sponsors are increasingly financing diagnostic R&D to secure drug market access, thereby aligning incentives across the value chain.

High Capital and Operational Costs for Advanced Molecular Platforms

Benchtop sequencers cost USD 500,000, while high-throughput systems exceed USD 1 million, creating adoption barriers for community hospitals. Annual reagent outlays over USD 300,000 press already thin laboratory margins, and average reagent-plus-analysis cost per comprehensive profile is USD 1,200 even as Medicare pays USD 3,000 per test. Leasing and reagent-rental contracts offset capital costs but lock labs into multiyear commitments. Low-volume institutions resort to send-out models, accepting 7-10-day turnaround times that delay therapy initiation. Economic hurdles thus restrict decentralization, particularly in emerging markets where capital financing is scarce.

Other drivers and restraints analyzed in the detailed report include:

Declining Sequencing Costs and Expanded Clinical NGS ReimbursementEmergence of Multiplex Syndromic Panels for Infectious Disease ManagementComplex and Evolving Regulatory Frameworks (EU IVDR, FDA LDT Rule)

For complete list of drivers and restraints, kindly check the Table Of Contents.

Geography Analysis

North America generated 42.54% of the 2025 revenue, driven by high per-capita spending and the rapid adoption of precision diagnostics by payers. CMS fee-schedule cuts in 2025 trimmed margins for low-complexity genomic tests, prompting labs to prioritize oncology panels with stronger reimbursement. Canada enlarged coverage to pharmacogenomics for antidepressants and anticoagulants, broadening pre-emptive genotyping in primary care. Liquid biopsy volumes surpassed 2 million U.S. samples in 2024, representing 80% of global activity.

The Asia-Pacific region is forecasted to grow at a 11.35% CAGR, underpinned by increasing funding for population genomics. Japan’s USD 1.8 billion initiative to sequence 1 million genomes by 2028 accelerates local instrument sales. China’s 2024 inclusion of NGS cancer panels with 70% reimbursement drives triple-digit volume growth in tier-1 cities. India’s private hospitals deploy NGS oncology profiling for out-of-pocket clients, while South Korean manufacturers expand PCR panel exports across Southeast Asia.

Europe faces IVDR-related product withdrawals as 38% of small IVD firms contemplate exit, tightening supply. Saudi Arabia’s Human Genome Program and the UAE's newborn sequencing initiatives are making the Middle East a new hotspot for genomic infrastructure investment. Brazil’s public health service funded molecular assays for tuberculosis and HIV drug resistance in 2024, catalyzing adoption despite budget constraints. Geographic momentum, therefore, hinges on reimbursement stability and domestic manufacturing capacity, factors that will dictate market share shifts through 2031.

List of Companies Covered in this Report:

10x Genomics Abbott Laboratories Agilent Technologies Beckton Dickinson bioMérieux Bio-Rad Laboratories Danaher DiaSorin Exact Sciences Roche Guardant Health Hologic Illumina LabCorp QIAGEN Seegene Siemens Healthineers Sysmex Thermo Fisher Scientific

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support

ページTOPに戻る

Table of Contents

1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Demand for Rapid Point-of-Care Molecular Diagnostics
4.2.2 Integration of Companion Diagnostics with Targeted Therapies
4.2.3 Declining Sequencing Costs and Expanded Clinical NGS Reimbursement
4.2.4 Emergence of Multiplex Syndromic Panels for Infectious Disease Management
4.2.5 Decentralization of Testing Through CLIA-Waived Platforms and Retail Clinics
4.2.6 Government-Funded Population Genomics and Pandemic Preparedness Programs
4.3 Market Restraints
4.3.1 High Capital and Operational Costs for Advanced Molecular Platforms
4.3.2 Complex and Evolving Regulatory Frameworks (EU IVDR, FDA LDT Rule)
4.3.3 Reimbursement Uncertainties for Broad Genomic Profiling and Liquid Biopsy
4.3.4 Shortage of Skilled Molecular Laboratory Workforce
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Buyers
4.7.2 Bargaining Power of Suppliers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitute Products
4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)
5.1 By Technology
5.1.1 PCR
5.1.2 Next-Generation Sequencing (NGS)
5.1.3 In Situ Hybridization
5.1.4 Chips & Microarrays
5.1.5 Mass Spectrometry
5.1.6 Other Technologies
5.2 By Application
5.2.1 Infectious Disease
5.2.2 Oncology
5.2.3 Pharmacogenomics
5.2.4 Microbiology
5.2.5 Genetic Disease Screening
5.2.6 Human Leukocyte Antigen Typing
5.2.7 Blood Screening
5.3 By Product
5.3.1 Reagents & Kits
5.3.2 Instruments & Systems
5.3.3 Software & Services
5.4 By Sample Type
5.4.1 Blood, Serum & Plasma
5.4.2 Urine
5.4.3 Other Sample Types (Saliva, Tissue, Swabs)
5.5 By End User
5.5.1 Hospitals
5.5.2 Diagnostic & Reference Laboratories
5.5.3 Academic & Research Institutes
5.5.4 Other End Users
5.6 Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest Of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 South Korea
5.6.3.5 Australia
5.6.3.6 Rest Of Asia-Pacific
5.6.4 Middle East And Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest Of Middle East And Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest Of South America

6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products & Services, And Recent Developments)
6.3.1 10x Genomics
6.3.2 Abbott Laboratories
6.3.3 Agilent Technologies Inc.
6.3.4 Becton, Dickinson And Company
6.3.5 bioMérieux SA
6.3.6 Bio-Rad Laboratories Inc.
6.3.7 Danaher
6.3.8 DiaSorin S.p.A.
6.3.9 Exact Sciences Corporation
6.3.10 F. Hoffmann-La Roche Ltd
6.3.11 Guardant Health
6.3.12 Hologic Inc.
6.3.13 Illumina Inc.
6.3.14 Labcorp
6.3.15 Qiagen N.V.
6.3.16 Seegene Inc.
6.3.17 Siemens Healthineers AG
6.3.18 Sysmex Corporation
6.3.19 Thermo Fisher Scientific Inc.

7 Market Opportunities & Future Outlook
7.1 White-Space & Unmet-Need Assessment